Oligonucleotide Synthesis Market Size to Exceed USD 9.68 Bn by 2032

The Oligonucleotide Synthesis Market, estimated at USD 4.69 Bn in 2025, is expected to exhibit a CAGR of 10.9% and reach USD 9.68 Bn by 2032.

The market growth is fueled by rising demand for advanced biotechnology solutions that improve healthcare outcomes, along with increasing adoption in areas such as drug development, diagnostics, and personalized medicine. Innovations in genomics, cell and gene therapies, and biomanufacturing, supported by strong R&D investments, are enhancing treatment effectiveness, efficiency, and accessibility. Furthermore, favorable regulatory support, strategic collaborations, and the growing focus on precision medicine are accelerating market expansion and opening new opportunities for industry participants.

Key market players are focusing on receiving funding for research and development activities for the synthesis of oligonucleotides, which will drive the global oligonucleotide synthesis market. For instance, on July 19, 2022, SynbiCITE, the UK’s National Centre for the Industrial Translation of Synthetic Biology, received a US$ 5.9 million funding commitment from SynBioVen, an investment  company  supporting the next generation of synthetic biology scientists, founders, and start-ups. The funding will enable the Imperial-hosted center to continue to support synthetic biology startups and SMEs, strengthen the emerging UK bio economy, and help unlock the societal benefits of synthetic biology.

Global Oligonucleotide Synthesis Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic had a positive impact on the global oligonucleotide synthesis market, owing to the fact that the market players and government authorities were focused on inorganic growth strategies such as agreement, to explore the oligonucleotide platform for the development of COVID-19 treatment.

For instance, in April 2020, Sarepta Therapeutics, Inc., a provider of precision genetic medicine, and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), the department of defense’s lead laboratory for medical biological defense research, entered into a cooperative research and development agreement (CRADA) to identify antisense oligonucleotides against SARS-CoV-2 for the potential treatment of COVID-19.

Furthermore, in April 2020, TriLink BioTechnologies, a subsidiary of  Maravai LifeSciences, and Imperial College London, a public research university located in the U.K., announced that they had entered into a partnership. Under this partnership, TriLink used its robust RNA manufacturing capabilities to respond to the global need for vaccine support against the COVID-19 pandemic. 

Global Oligonucleotide Synthesis Market: Key Developments

On March 15, 2022, the ACS Green Chemistry Institute Pharmaceutical Roundtable (GCIPR) announced a partnership with the ACS Green Chemistry Institute. The ACS GCIPR is seeking a one-year Research and development commitment to assist the Roundtable’s Greener Oligonucleotide Initiative. The focus of the research and development will be on improving the sustainability of oligonucleotide manufacturing by addressing one of the environmental challenges facing the current process.

On December 13, 2022, GSK plc., a pharmaceutical and biotechnology company, and Wave Life Sciences Ltd., a clinical-stage genetic medicines company, announced a strategic collaboration to advance oligonucleotide therapeutics, including Wave’s preclinical RNA editing program targeting alpha-1 antitrypsin deficiency (AATD), WVE-006. The discovery collaboration has an initial four-year research term. It combines GSK’s unique insights from human genetics, as well as its global development and commercial capabilities, with Wave’s proprietary discovery and drug development platform, PRISM.

Browse 55 Market Data Tables and 38 Figures spread through 198 Pages and in-depth TOC on “Global Oligonucleotide Synthesis Market”- Forecast to 2030, Global Oligonucleotide Synthesis Market, by Equipment and Services (Equipment/Synthesizer{Nucleic Acid Synthesizer and Peptide Synthesizer} Reagents, Services {Oligo Synthesis, Modification and Purification), by Technology (Column-based and Microarray-based), by Nucleic Acid (DNA and RNA), by Application (Drug Discovery and Therapeutics), by End User (Academic Research Institutes, Diagnostic Laboratories and Pharmaceutical-biotechnology Companies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/oligonucleotide-synthesis-market-4257

Key Takeaways of the Global Oligonucleotide Synthesis Market:

• The global oligonucleotide synthesis market is expected to exhibit a CAGR of 10.9% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the global oligonucleotide synthesis market.
• Among Nucleic acid, DNA Segment is expected to increase and this is expected to drive the growth of the global oligonucleotide synthesis market over the forecast period. For instance, increasing adoption of inorganic growth strategies such as license agreements by market players for the synthesis of oligonucleotides is expected to boost the segment growth over the forecast period. For instance, in August 2022, Codexis, Inc., a protein engineering company, and Molecular Assemblies, Inc., a private life sciences company, announced that they had signed a license and enzyme supply agreement enabling Molecular Assemblies to use its Fully Enzymatic Synthesis technology. Under this agreement, the companies will work together to develop the supercharged TdT enzyme to advance fully enzymatic DNA synthesis for the production of long, pure, and precise oligonucleotides and to accelerate innovation in many areas.
• Among region, North America is expected to be the dominant region in the global oligonucleotide synthesis market, owing to the increasing expansion of the product offering using research and development activities, and is expected to drive the gowth of the global oligonucleotide synthesis market over the forecast period. For instance, in 2022, CatSci, an innovation partner for medicine development, made a lot of investment to support the development of oligonucleotide capability. Now the company will be able to manufacture oligonucleotides from nanomole quantities up to 30 grams using methods like solid-phase synthesis and also carry out research into new manufacturing approaches aligned with its green chemistry commitments.
• Major players operating in the global oligonucleotide synthesis market are Thermo Fisher Scientific Inc., Merck KGaA,  Danaher Corporation,  Twist Bioscience,  STA Pharmaceutical Co. Ltd.,  KINOVATE LIFE SCIENCES,  CUSABIO TECHNOLOGY LLC,  Synbio Technologies,  GENEWIZ,  Agilent Technologies, Inc.,  Maravai LifeSciences Holdings, Inc.,  Biogen,  Eurofins Scientific,  Sarepta Therapeutics, Inc.,  LGC Limited,  Kaneka Corporation,  Biotage and Nitto Denko Corporation